Inovio Pharmaceuticals, Inc.
General ticker "INO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $72.3M (TTM average)
Inovio Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 21.2%.
Estimated limits based on current volatility of 3.6%: low 1.92$, high 2.06$
Factors to consider:
- Total employees count: 134 (+9.8%) as of 2024
- Top business risk factors: Significant losses, Supply chain disruptions, Litigation risks, Acquisition/divestiture risks, Poor capital deployment decisions
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.70$, 5.54$]
- 2025-12-31 to 2026-12-31 estimated range: [1.38$, 4.35$]
Financial Metrics affecting the INO estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -209.90 <= 0.33
- Positive: Investing cash flow per share per price, % of 209.89 > -0.66
- Positive: 41.86 < Shareholder equity ratio, % of 60.52 <= 63.39
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term INO quotes
Long-term INO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $10.26MM | $0.83MM | $0.22MM |
| Operating Expenses | $277.84MM | $144.77MM | $112.62MM |
| Operating Income | $-267.57MM | $-143.94MM | $-112.40MM |
| Non-Operating Income | $-10.08MM | $13.53MM | $8.31MM |
| Interest Expense | $1.25MM | $1.22MM | $0.18MM |
| R&D Expense | $187.65MM | $86.68MM | $75.62MM |
| Income(Loss) | $-277.65MM | $-130.41MM | $-104.09MM |
| Other Income(Loss) | $-2.17MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-279.82MM | $-135.12MM | $-107.25MM |
| Stockholders Equity | $222.36MM | $117.35MM | $68.50MM |
| Assets | $348.53MM | $170.95MM | $113.20MM |
| Operating Cash Flow | $-216.22MM | $-124.37MM | $-104.08MM |
| Capital expenditure | $0.97MM | $0.32MM | $0.49MM |
| Investing Cash Flow | $109.59MM | $87.36MM | $104.07MM |
| Financing Cash Flow | $81.84MM | $5.00MM | $51.48MM |
| Earnings Per Share** | $-14.07 | $-6.09 | $-3.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.